Compare HLX & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | HROW |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | United States | United States |
| Employees | N/A | 373 |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 1996 | N/A |
| Metric | HLX | HROW |
|---|---|---|
| Price | $8.64 | $42.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $11.50 | ★ $69.86 |
| AVG Volume (30 Days) | ★ 1.3M | 774.3K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $876,561,000.00 | N/A |
| Revenue This Year | $2.05 | $31.62 |
| Revenue Next Year | $5.46 | $50.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $5.52 | $28.54 |
| 52 Week High | $10.75 | $54.98 |
| Indicator | HLX | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 34.57 | 71.69 |
| Support Level | $8.58 | $40.61 |
| Resistance Level | $10.54 | $51.01 |
| Average True Range (ATR) | 0.34 | 2.10 |
| MACD | -0.09 | 1.08 |
| Stochastic Oscillator | 14.08 | 98.96 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. The Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S., and it also has its presence in North Sea, Brazil, Asia Pacific, West Africa, and Other.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.